Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sequencing capacity ramp-ups, antibody pipeline milestones, and cash-burn assumptions make Twist Bioscience’s SEC disclosures uniquely complex. Locating gene-synthesis revenue mix in the Twist Bioscience annual report 10-K simplified filing or tracing collaboration updates buried in an 8-K often means scrolling through hundreds of pages. Stock Titan solves this pain point by turning dense biotechnology jargon into concise insights, giving you twist bioscience SEC filings explained simply without losing critical detail.
Our AI reads every document the instant it hits EDGAR, delivering Twist Bioscience Form 4 insider transactions real-time, red-flagging risk-factor changes, and extracting segment metrics into dashboards. Whether you’re searching for a twist bioscience quarterly earnings report 10-Q filing, a sudden twist bioscience 8-K material events explained, or the latest twist bioscience proxy statement executive compensation tables, the platform highlights exactly where the numbers live and what they mean. Smart tags link cash-flow shifts to R&D spending so you can perform twist bioscience earnings report filing analysis in minutes, not hours.
Need to monitor management moves before the next capital raise? Track every twist bioscience insider trading Form 4 transactions alert or dive deeper into twist bioscience executive stock transactions Form 4 to spot buying trends. From cost-of-goods disclosures that impact gross margin to litigation notes that could reshape IP value, our expert commentary keeps you ahead. If you’re focused on understanding Twist Bioscience SEC documents with AI, start here—comprehensive coverage, real-time updates, and plain-English explanations for every filing type.
Twist Bioscience Corporation (TWST) has filed a Form 144 notice covering the potential sale of 3,189 common shares through Fidelity Brokerage, with an estimated market value of $90,453. The proposed trade window opens on 04 Aug 2025. The company reports 59,916,141 shares outstanding, so the planned sale represents roughly 0.005 % of the float—immaterial at the corporate level.
The shares derive from restricted-stock that vested on 01 Aug 2025 and are held in the account of Patrick Finn. Over the previous three months, Finn has already sold 27,118 shares for total gross proceeds of $894,853, indicating an ongoing disposition program.
Form 144 is only a notice; execution, timing, and price may vary, and the filer certifies no undisclosed material adverse information. No operating, earnings or guidance data accompany this filing.
Twist Bioscience Corp. (TWST) – Form 144 filing discloses that insider Patrick Finn plans to sell 2,232 common shares through Fidelity Brokerage on or about 23 Jul 2025. At the stated market value of $79,773, the proposed sale equals roughly 0.004% of the company’s 59.9 million shares outstanding.
The notice also lists five prior sales by Finn during the last three months, totaling 26,944 shares and $897,390 in gross proceeds (dates: 23 Apr, 5 May, 8 May, 21 May, 2 Jul 2025). The shares were acquired via restricted-stock vesting on 22 Jul 2025, indicating compensation-related disposal rather than open-market buying and selling. By signing Form 144, the filer attests to possessing no undisclosed adverse information.
Though the absolute size is small, the continued disposition may signal a modestly negative insider sentiment trend that investors could monitor.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
